Our health depends on our body’s ability to maintain carefully-calibrated metabolic balance.
Metabolic pathways, including glucose metabolism and fat synthesis, are highly integrated and regulated within cells, organs and across the whole body to maintain homeostasis. When this balance is disrupted by environmental or genetic factors, it can result in serious and potentially life-threatening diseases.
Akero Therapeutics is developing best-in-class medicines that treat these serious diseases by restoring metabolic balance.
Our lead clinical program, AKR-001, is a treatment for non-alcoholic steatohepatitis (NASH), rapidly emerging as the leading cause of liver disease around the world. AKR-001 is a novel long-acting fibroblast growth factor 21 (FGF21) agonist, with the potential to make a meaningful impact on the lives of those living with NASH, and other serious metabolic diseases.